HLS Therapeutics Inc.

TSX:HLS.TO

Drug Manufacturers - Specialty & Generic

Healthcare
$3.76 -2.51%

-$0.11 today

Market cap
$116.32M
Beta
0.85
P/E (TTM)
-9.6
EPS (TTM)
-$0.33
52W Low $0.00High $5.77

Volume 0.04M

Average 0.01M

HLS.TO EBITDA Margin

EBITDA as a percentage of revenue.

HLS Therapeutics Inc.TSX: HLS.TO

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 25.8%

EBITDA Margin was 25.8% in Q1 FY2026, up 2.7 pp from a year earlier. On a trailing-twelve-month basis it was 31.9%, up 6.2 pp year over year. Over 3 fiscal years it widened by 2.6 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 35.1% for the fiscal year ending Dec 2026, up from 31.9% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
25.8%-11.7 pp QoQ
Last fiscal yearDec 2025
31.9%+1.5 pp YoY
LTMMar 2026
31.9%+6.2 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+2.7 pp-7.5 pp-10.1 pp
1 year+1.5 pp+3.2 pp+1.7 pp
3 years+2.6 pp+0.3 pp-2.3 pp
5 years+6.9 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
31.9%
Year-over-year change
+1.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How HLS.TO compares with its peers on the latest reported figures

  • HLS.TO's LTM Mar 2026 EBITDA Margin of 31.9% is the highest of the 6 companies compared; the peer median is 6.3%.
  • Its year-over-year change of +6.2 pp is the 2nd highest of 6, against a peer median of -12.3 pp.
  • Over three fiscal years its change of +2.6 pp compares with a peer median of +0.1 pp.
HLS.TO Competitors Peer median
EBITDA Margin for HLS.TO and competitors
Company Period LTM level YoY 3-year change
HLS.TOHLS Therapeutics Inc.LTM Mar 202631.9% +6.2 pp+2.6 pp
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 202620.9% +0.5 pp+0.1 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
ETONEton Pharmaceuticals, Inc.LTM Mar 20266.3% +9.1 pp+39.4 pp
CPIXCumberland Pharmaceuticals Inc.LTM Mar 2026-4.3% -12.3 pp+5.9 pp
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-102.7% -35.0 pp-65.4 pp
NERVMinerva Neurosciences, Inc.FY2025— ——
Peer median (excluding HLS.TO) 6.3%-12.3 pp+0.1 pp

Competitors are the stored peer set for HLS.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue60.01M61.47M63.07M56.62M56.47M
Cost of Revenue3.97M4.98M7.62M9M32.46M
Gross Profit56.04M56.49M55.45M47.62M24.01M
Gross Margin93.4%91.9%87.9%84.1%42.5%
Research & Development00000
Selling, General & Admin32.06M35.58M28.29M26.93M22M
Operating Expenses62.32M69.98M55.45M55.31M28.19M
Depreciation & Amortization30.26M34.4M31.94M22.72M22.2M
EBITDA25.41M18M12.88M17.22M18.02M
EBITDA Margin42.3%29.3%20.4%30.4%31.9%
Operating Income(6.24M)(13.44M)(10.35M)(7.69M)(4.18M)
Operating Margin-10.4%-21.9%-16.4%-13.6%-7.4%
Interest Income44K57K350K319K108.87K
Interest Expense6.96M7.32M8.75M10.08M7.22M
Other Income / Expenses(5.52M)(10.23M)(17.45M)(7.9M)(8.92M)
Income Before Tax(11.81M)(23.72M)(27.8M)(15.58M)(13.1M)
Pre-Tax Margin-19.7%-38.6%-44.1%-27.5%-23.2%
Income Tax Expense1.31M(124K)(272K)4.07M(452.79K)
Net Income(13.12M)(23.6M)(27.53M)(19.66M)(12.65M)
Net Margin-21.9%-38.4%-43.6%-34.7%-22.4%
EPS (Basic)(0.41)(0.73)(0.85)(0.62)(0.40)
EPS (Diluted)(0.41)(0.73)(0.85)(0.62)(0.40)
Weighted Avg Shares32.18M32.33M32.26M31.84M31.53M
Weighted Avg Shares (Diluted)32.18M32.43M32.26M31.84M31.53M

HLS Therapeutics Inc.

TSX:HLS.TO

Intrinsic Alpha fair value

Locked

Current Price

$3.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.